Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Investigating the role of amyloid beta, oxidative stress, and mitochondrial dysfunction in pre-symptomatic Alzheimer's disease

EF 2016-17

Résumé
There are currently no cures nor preventative therapeutics for Alzheimer's disease (AD) which is the leading cause of dementia in the elderly. Clinical symptoms of AD including memory loss, appear late in the disease progression. Therefore, it is critical to study the earliest, pre-symptomatic stages of AD and enable the development of preventative therapeutics that halt AD before memory loss occurs. In humans, the earliest stages of AD are difficult to study because they occur decades before clinical symptoms appear, thus transgenic (Tg) AD animal models have been developed. During these early stages of AD there is a build-up of the protein amyloid beta (Abeta) that at late stages, causes damage to neurons by producing reactive oxygen species (ROS) and disrupting mitochondrial function. The exact location and time-frame when Abeta begins to build-up, and how it initiates damage to neurons at the earliest stages of AD is not understood. The aim of my project is to understand the earliest, pre-symptomatic stages of AD by studying the role of Abeta, ROS production, and mitochondrial dysfunction in AD progression. Based on these findings, I will assess the efficacy of therapeutics that prevent these disease aggravating processes. The project will determine when, where, and how disease aggravating processes start during the earliest stages of AD. Using novel probes available through an interdisciplinary collaboration, and innovative methods, the ROS levels and mitochondria function will be measured in the brains of both Tg (AD) and healthy rats. Areas of the brain that are the initial sites of Abeta build-up will be assessed in order to understand the earliest disease processes of AD. These results will help determine promising therapeutic interventions for AD and a time-frame for when treatments would be most effective. By interrupting the early disease progression of AD, patients can be helped before any memory loss or irreversible damage occurs.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
365464
Name
Foret Morgan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the role of amyloid beta, oxidative stress, and mitochondrial dysfunction in pre-symptomatic Alzheimer's disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Early Amyloid Pathology; Ex-Vivo Imaging; Intracellular Amyloid Beta; Mitochondria Dysfunction; Novel Ros Detecting Fluorescent Probes; Pre-Clinical Stages; Primary Neuron Culture; Reactive Oxygen Species (Ros); Transgenic Rat Model
Abstract
There are currently no cures nor preventative therapeutics for Alzheimer's disease (AD) which is the leading cause of dementia in the elderly. Clinical symptoms of AD including memory loss, appear late in the disease progression. Therefore, it is critical to study the earliest, pre-symptomatic stages of AD and enable the development of preventative therapeutics that halt AD before memory loss occurs. In humans, the earliest stages of AD are difficult to study because they occur decades before clinical symptoms appear, thus transgenic (Tg) AD animal models have been developed. During these early stages of AD there is a build-up of the protein amyloid beta (Abeta) that at late stages, causes damage to neurons by producing reactive oxygen species (ROS) and disrupting mitochondrial function. The exact location and time-frame when Abeta begins to build-up, and how it initiates damage to neurons at the earliest stages of AD is not understood. The aim of my project is to understand the earliest, pre-symptomatic stages of AD by studying the role of Abeta, ROS production, and mitochondrial dysfunction in AD progression. Based on these findings, I will assess the efficacy of therapeutics that prevent these disease aggravating processes. The project will determine when, where, and how disease aggravating processes start during the earliest stages of AD. Using novel probes available through an interdisciplinary collaboration, and innovative methods, the ROS levels and mitochondria function will be measured in the brains of both Tg (AD) and healthy rats. Areas of the brain that are the initial sites of Abeta build-up will be assessed in order to understand the earliest disease processes of AD. These results will help determine promising therapeutic interventions for AD and a time-frame for when treatments would be most effective. By interrupting the early disease progression of AD, patients can be helped before any memory loss or irreversible damage occurs.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Foret, Morgan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~